Trial Profile
An impact of white blood cell (WBC) counts at presentation on molecular response in newly diagnosed chronic-phase chronic myeloid leukemia patients treated with Imatinib.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Jun 2016
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Pharmacodynamics; Therapeutic Use
- 30 Jun 2016 New trial record